 BEIJING--BUSINESS WIRE--Sinovac Biotech Ltd. NASDAQ:SVA Sinovac or the Company, a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration NMPA has approved and issued a Product license for the Companys 23-Valent Pneumococcal Polysaccharide PPV Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above. Mr. Weidong Yin, Chairman, President and CEO of Sinova 